HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tibor Keler Selected Research

rindopepimut

1/2020Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
10/2017Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
6/2015A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tibor Keler Research Topics

Disease

39Neoplasms (Cancer)
01/2022 - 03/2004
9Melanoma (Melanoma, Malignant)
01/2022 - 12/2003
5Lymphoma (Lymphomas)
10/2020 - 11/2003
3Triple Negative Breast Neoplasms
01/2022 - 11/2017
3Breast Neoplasms (Breast Cancer)
01/2022 - 03/2012
3Hodgkin Disease (Hodgkin's Disease)
12/2020 - 11/2003
3Carcinoma (Carcinomatosis)
12/2020 - 03/2004
3Glioblastoma (Glioblastoma Multiforme)
01/2020 - 06/2015
3Infections
02/2017 - 10/2010
2Fatigue
12/2020 - 10/2017
2Renal Cell Carcinoma (Grawitz Tumor)
12/2020 - 12/2016
2Neoplasm Metastasis (Metastasis)
11/2017 - 11/2014
2Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
07/2007 - 11/2003
2Communicable Diseases (Infectious Diseases)
04/2005 - 12/2004
2Autoimmune Diseases (Autoimmune Disease)
04/2005 - 12/2004
1Hematologic Neoplasms (Hematological Malignancy)
12/2020
1HIV Infections (HIV Infection)
11/2019
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2019
1Tetanus
01/2018
1Myocardial Infarction
01/2018
1Thrombocytopenia (Thrombopenia)
10/2017
1Headache (Headaches)
10/2017
1Pulmonary Embolism
10/2017
1Adenocarcinoma
12/2016
1Leukemia
07/2012
1Urinary Bladder Neoplasms (Bladder Cancer)
06/2011
1Testicular Neoplasms (Testicular Cancer)
01/2011
1Malaria
10/2010
1Ovarian Neoplasms (Ovarian Cancer)
09/2008
1Body Weight (Weight, Body)
10/2006
1Anthrax
10/2006
1Necrosis
02/2006

Drug/Important Bio-Agent (IBA)

14VaccinesIBA
12/2020 - 12/2003
13Monoclonal AntibodiesIBA
01/2018 - 11/2003
9varlilumabIBA
01/2022 - 07/2012
9AntigensIBA
01/2019 - 03/2004
8Proteins (Proteins, Gene)FDA Link
11/2017 - 03/2004
7AntibodiesIBA
10/2020 - 04/2005
6Neoplasm Antigens (Tumor Antigens)IBA
03/2012 - 03/2004
5glembatumumab vedotinIBA
01/2022 - 11/2014
5Immunoconjugates (Immunoconjugate)IBA
12/2020 - 11/2014
4Glycoproteins (Glycoprotein)IBA
01/2022 - 11/2014
4Mannose ReceptorIBA
06/2011 - 03/2004
3Immunoglobulins (Immunoglobulin)IBA
12/2020 - 07/2007
3AutoantigensIBA
10/2020 - 06/2005
3rindopepimutIBA
01/2020 - 06/2015
3epidermal growth factor receptor VIIIIBA
01/2020 - 06/2015
3EpitopesIBA
01/2018 - 03/2004
3Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
07/2011 - 03/2004
3Cancer VaccinesIBA
07/2011 - 03/2004
2flt3 ligand protein (flt3 ligand)IBA
10/2020 - 11/2019
2Immune Checkpoint InhibitorsIBA
10/2020 - 04/2014
2keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA
01/2020 - 10/2017
2Peptides (Polypeptides)IBA
01/2018 - 02/2005
2Temozolomide (Temodar)FDA LinkGeneric
10/2017 - 06/2015
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
10/2017 - 06/2011
2poly ICLCIBA
04/2014 - 06/2011
2resiquimodIBA
04/2014 - 06/2011
2Toll-Like Receptors (Toll-Like Receptor)IBA
04/2014 - 07/2011
2Toll-Like Receptor AgonistsIBA
04/2014 - 06/2011
2CDX 1307IBA
07/2011 - 06/2011
2CytokinesIBA
09/2008 - 02/2006
1Mucin-1 (CA 15-3 Antigen)IBA
12/2020
1Epidermal Growth Factor (EGF)IBA
01/2020
1Bevacizumab (Avastin)FDA Link
01/2020
1Protein Subunit VaccinesIBA
01/2018
1OVA-8IBA
01/2018
1chenodeoxycholate sulfate conjugate (CDCS)IBA
01/2018
1OvalbuminIBA
01/2018
1Immunoglobulin G (IgG)IBA
12/2017
1Polysaccharides (Glycans)IBA
02/2017
1Differentiation AntigensIBA
12/2016
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2016
1ErbB Receptors (EGF Receptor)IBA
06/2015
1AnthracyclinesIBA
11/2014
1taxaneIBA
11/2014
1Capecitabine (Xeloda)FDA Link
11/2014
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
07/2012
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
07/2012
1MesothelinIBA
09/2009
1cadherin 5IBA
09/2008
1Pattern Recognition ReceptorsIBA
05/2007
1LigandsIBA
01/2007
1anthrax toxin (anthrax lethal factor)IBA
10/2006
1Anthrax Vaccines (Vaccines, Anthrax)IBA
10/2006
1Neutralizing AntibodiesIBA
10/2006
1Mitogen-Activated Protein KinasesIBA
02/2006
1InterleukinsIBA
02/2006
1Interleukin-6 (Interleukin 6)IBA
02/2006
1Fc gamma receptor IIAIBA
07/2005

Therapy/Procedure

13Therapeutics
01/2022 - 10/2006
11Immunotherapy
10/2020 - 11/2003
4Drug Therapy (Chemotherapy)
10/2017 - 09/2008
1Cell- and Tissue-Based Therapy (Cell Therapy)
01/2022
1Investigational Therapies (Experimental Therapy)
01/2022
1Immunomodulation
10/2020
1Radiotherapy
10/2020
1Intradermal Injections
10/2017
1Subcutaneous Injections
12/2016
1Intramuscular Injections
10/2006